X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (458) 458
female (348) 348
middle aged (278) 278
index medicus (277) 277
oncology (244) 244
adult (231) 231
aged (229) 229
bridged-ring compounds - administration & dosage (199) 199
bridged-ring compounds - therapeutic use (183) 183
male (176) 176
breast neoplasms - drug therapy (175) 175
bridged-ring compounds - adverse effects (171) 171
chemotherapy (160) 160
taxoids - administration & dosage (158) 158
antineoplastic combined chemotherapy protocols - therapeutic use (143) 143
cancer (135) 135
taxoids - adverse effects (124) 124
breast cancer (113) 113
taxoids - therapeutic use (107) 107
breast neoplasms - pathology (106) 106
paclitaxel (98) 98
treatment outcome (98) 98
antineoplastic combined chemotherapy protocols - adverse effects (97) 97
animals (96) 96
bridged-ring compounds - pharmacology (95) 95
docetaxel (91) 91
antineoplastic agents - adverse effects (83) 83
antineoplastic agents - therapeutic use (82) 82
pharmacology & pharmacy (79) 79
care and treatment (67) 67
therapy (62) 62
medicine & public health (57) 57
neoplasm staging (56) 56
taxane (56) 56
aged, 80 and over (54) 54
trial (54) 54
anthracyclines - administration & dosage (53) 53
deoxycytidine - analogs & derivatives (51) 51
taxoids (51) 51
analysis (50) 50
hematology, oncology and palliative medicine (50) 50
drug administration schedule (49) 49
retrospective studies (49) 49
disease-free survival (47) 47
mice (44) 44
neoplasm metastasis (44) 44
research (44) 44
anthracyclines (42) 42
drug resistance, neoplasm (42) 42
prognosis (41) 41
deoxycytidine - administration & dosage (40) 40
survival analysis (40) 40
metastasis (39) 39
survival (39) 39
anthracyclines - therapeutic use (37) 37
antineoplastic combined chemotherapy protocols - administration & dosage (37) 37
carcinoma (37) 37
anthracyclines - adverse effects (36) 36
fluorouracil - administration & dosage (36) 36
ovarian neoplasms - drug therapy (36) 36
dose-response relationship, drug (35) 35
cisplatin (34) 34
clinical trials as topic (34) 34
metastatic breast cancer (34) 34
antineoplastic agents - administration & dosage (33) 33
cisplatin - administration & dosage (33) 33
clinical trials (33) 33
article (32) 32
lung neoplasms - drug therapy (32) 32
disease progression (31) 31
follow-up studies (31) 31
health aspects (31) 31
time factors (31) 31
rats (30) 30
drug therapy (29) 29
obstetrics & gynecology (29) 29
prospective studies (29) 29
quality of life (29) 29
survival rate (29) 29
taxoids - pharmacology (29) 29
adjuvant chemotherapy (28) 28
capecitabine (28) 28
carcinoma, non-small-cell lung - drug therapy (28) 28
patients (28) 28
ramipril (28) 28
risk factors (28) 28
women (28) 28
cancer therapies (27) 27
efficacy (27) 27
oncology, experimental (27) 27
phase-ii (27) 27
taxanes (27) 27
toxicity (27) 27
breast neoplasms - mortality (26) 26
cancer patients (26) 26
chemotherapy, adjuvant (26) 26
trastuzumab (26) 26
bridged-ring compounds - chemistry (25) 25
fluorouracil - adverse effects (25) 25
anthracycline (24) 24
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (490) 490
Japanese (10) 10
Chinese (7) 7
Italian (5) 5
German (4) 4
French (3) 3
Russian (3) 3
Finnish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2014, Volume 148, Issue 3, pp. 553 - 561
Journal Article
Supportive Care in Cancer, ISSN 0941-4355, 4/2018, Volume 26, Issue 4, pp. 1019 - 1028
Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy... 
Pain Medicine | Nursing | Rehabilitation Medicine | Exercise | Medicine & Public Health | Nursing Research | Oncology | CIPN | Neuropathy | MANAGEMENT | PREVENTION | PREVALENCE | CANCER SURVIVORS | PAIN | ONCOLOGY | PREDICTORS | CLINICAL-TRIALS | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PHYSICAL-ACTIVITY | QUALITY-OF-LIFE | OUTCOMES | Exercise Therapy - methods | Peripheral Nervous System Diseases - chemically induced | Humans | Middle Aged | Vinca Alkaloids - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Peripheral Nervous System Diseases - therapy | Male | Peripheral Nervous System Diseases - physiopathology | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Taxoids - administration & dosage | Organoplatinum Compounds - administration & dosage | Vinca Alkaloids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Neoplasm Staging | Neoplasms - pathology | Bridged-Ring Compounds - administration & dosage | Organoplatinum Compounds - adverse effects | Taxoids - adverse effects | Alkaloids | Chemotherapy | Health aspects | Analysis | Mortality | Cancer | Clinical trials | Breast cancer | Peripheral neuropathy | Index Medicus | exercise | neuropathy
Journal Article
JAMA, ISSN 0098-7484, 02/2017, Volume 317, Issue 6, pp. 606 - 614
Journal Article
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 6/2018, Volume 169, Issue 2, pp. 333 - 340
The purpose of this two-cohort Phase II trial was to estimate the pathologic complete response (pCR: ypT0/is ypN0) rate when trastuzumab plus pertuzumab are... 
Neoadjuvant therapy | HER-2-positive | Medicine & Public Health | Pertuzumab | Pathological complete response | Oncology | Breast cancer | Trastuzumab | MULTICENTER | OPEN-LABEL | COMBINATION | PLUS TRASTUZUMAB | CHEMOTHERAPY | ADJUVANT TRASTUZUMAB | LAPATINIB | THERAPY | ONCOLOGY | CLINICAL-TRIALS | CONCURRENT | Cyclophosphamide - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Epirubicin - administration & dosage | Cyclophosphamide - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Breast Neoplasms - epidemiology | Antibodies, Monoclonal, Humanized - adverse effects | Paclitaxel - adverse effects | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoadjuvant Therapy - adverse effects | Bridged-Ring Compounds - adverse effects | Bridged-Ring Compounds - administration & dosage | Drug-Related Side Effects and Adverse Reactions - classification | Epirubicin - adverse effects | Anthracyclines | Cyclophosphamide | Analysis | Adjuvant treatment | Clinical trials | Product development | Health aspects | Cancer
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 4/2018, Volume 168, Issue 3, pp. 625 - 630
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 14, pp. 2375 - 2389
Journal Article
Annals of Oncology, ISSN 0923-7534, 2014, Volume 25, Issue 8, pp. 1570 - 1577
Journal Article